/R E P E A T -- Claigan Webinar - Are Canadian Products Safer than Products in Poland?/
OTTAWA, ON, Aug. 5, 2025 /CNW/ - On 13 August 2025, Claigan Environmental Inc. (www.claigan.com) will present and compare the findings of restricted materials testing on consumer products from Canada and Poland.
Over the last two years, Claigan tested sixty (60) similar consumer products sourced from Canada and Poland for restricted materials. In particular, we focused on DEHP (which causes attention deficit) and lead (a reproductive toxin and carcinogen).
This webinar will look at real restricted materials test data concerning products you buy and touch everyday. Whose products do you think have the higher risk? Is it Poland? Or is it Canada? Attend this webinar to find out.
The main topics to be covered in this webinar are:
Which products are safer?
Levels of carcinogens and reproductive toxins
Effects of the levels detected
% of products tested with harmful levels of chemicals
Comparison of product types and level of harm
Are the same products found in the US and the rest of the EU?
Due to the interest in these topics, two (2) webinars will be held on August 13 to accommodate a larger audience.
About Claigan Environmental (www.claigan.com)
Claigan is the leading provider of restricted materials compliance. Claigan has tested tens of thousands of products for restricted materials compliance and offers complete cost effective solutions for even the most complex products. Claigan is an ISO 17025 certified laboratory and is dedicated to providing practical solutions for supply chain due diligence and social responsibility. At Claigan, we believe in 'Less Journey. More Results.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
36 minutes ago
- Cision Canada
Health Canada Approves KEYTRUDA® for Patients with Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma Tumours that are PD-L1 (CPS) Positive as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as Monotherapy Français
Approval is based on KEYNOTE-689 Phase III Clinical Trial Results KIRKLAND, QC, Aug. 13, 2025 /CNW/ -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has granted approval for KEYTRUDA ® (pembrolizumab), Merck's anti-PD-1 therapy, for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumours express PD-L1 (Combined Positive Score [CPS] ≥ 1), as determined by a validated test, as neoadjuvant treatment as monotherapy, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as monotherapy. The approval is based on data from the Phase 3 KEYNOTE-689 trial, which demonstrated positive clinical outcomes in patients with resectable locally advanced HNSCC whose tumours expressed PD-L1 (CPS ≥ 1). Perioperative KEYTRUDA ® in combination with adjuvant radiotherapy with or without cisplatin reduced the risk of event free survival (EFS) by 30% (Hazard Ration [HR]=0.70 [95% Confidence Interval [CI]: 0.55–0.89; p=0.0014]) compared to adjuvant radiotherapy with or without cisplatin. "We know that head and neck squamous cell carcinomas present significant treatment challenges because of their complexity," said André Galarneau, PhD, Executive Director & Vice President, Oncology Business Unit at Merck Canada. "The introduction of a perioperative anti-PD-1 treatment option for eligible patients in Canada represents an important development with the potential to make a meaningful difference for patients and their families impacted by this disease." About KEYNOTE-689 KEYNOTE-689 is a randomized, multicenter, open label, active-controlled Phase III trial ( NCT03765918) evaluating pembrolizumab in patients with resectable locally advanced (Stage III-IVA) head and neck squamous cell carcinoma (HNSCC). Randomization was stratified by primary tumour site (oropharynx/oral cavity vs. larynx vs. hypopharynx), tumour stage (III vs. IVA) and PD-L1 status (Tumour Proportion Score [TPS] ≥ 50% vs TPS < 50%). The study enrolled 714 patients who were randomized (1:1) to receive one of two treatment arms: Neoadjuvant pembrolizumab 200 mg for 2 cycles every 3 weeks prior to surgical resection. Within 6 weeks following surgery, pembrolizumab 200 mg for 3 cycles in combination with either radiation + 3 cycles of cisplatin 100 mg/m 2 every 3 weeks for patients with high-risk pathological features after surgery or radiation alone for patients without high-risk pathological features after surgery. This was followed by pembrolizumab 200 mg every 3 weeks for up to 12 cycles. No neoadjuvant treatment prior to surgery. Within 6 weeks following surgery, either radiation + 3 cycles of cisplatin 100 mg/m 2 every 3 weeks for patients with high-risk pathological features after surgery or radiation alone for patients without high-risk pathological features after surgery. High-risk pathological features included the presence of positive margins or extranodal extension following surgical resection. Treatment with pembrolizumab continued until completion of the treatment (17 cycles), disease progression that precluded definitive surgery, disease recurrence in the adjuvant phase, disease progression for those who did not undergo surgery or had incomplete resection and entered the adjuvant phase, or unacceptable toxicity. Assessment of tumour status was performed prior to surgery at Week 6 in the neoadjuvant phase. Following the start of the adjuvant phase, assessment of tumour status was performed 12 weeks after the end of RT ± cisplatin treatment and then every 3 months until the end of Year 3; then every 6 months thereafter up to the end of Year 5. The primary efficacy outcome measure was event-free survival (EFS) by Blinded Independent Central Review (BICR) defined as the time from randomization to the first occurrence of any of the following events: progression of disease that precludes definitive surgery, local or distant disease progression or recurrence, or death due to any cause. Secondary primary malignancy was not considered an event. An additional efficacy outcome measure was overall survival (OS). Among the CPS ≥1 population, at the time of the first pre-specified interim analysis, the EFS HR was 0.70 (95% CI, 0.55-0.89; p=0.00140) and the number of events was 128 (37%) in the pembrolizumab arm versus 156 (47%) in the RT +/- cisplatin arm. The median EFS was 59.7 months (95% CI, 37.9-not reached) versus 29.6 months (95% CI, 19.5-41.9), in the pembrolizumab and RT +/- cisplatin arms respectively. The most common treatment-related adverse events for patients treated with pembrolizumab in KEYNOTE-689 (reported in at least 20% of patients) were radiation skin injury and stomatitis. The most common Grade 3-5 treatment-related adverse events (reported in at least 5% of patients) were stomatitis (11.6%), lymphocyte count decreased (5.5%), and neutrophil count decreased (5.3%). For complete information, refer to the KEYTRUDA ® product monograph. About head and neck cancer Head and neck cancer are comprised of a group of cancers that develop in or around the mouth, nose, throat, sinuses, larynx or voice box and saliva glands. In Canada, it was estimated that there were approximately 8,100 new cases of head and neck cancer diagnosed and more than 2,100 deaths from the disease in 2024. Most head and neck cancers begin in the squamous cells that line the mucosal surfaces such as the mouth, throat and voice box. There are several factors that greatly increase the risk of developing head and neck cancer, including tobacco and alcohol use, human papillomavirus (HPV), occupation exposure to certain substances, genetic history and pool oral hygiene. About KEYTRUDA ® KEYTRUDA ® is an anti-programmed death receptor-1 (anti-PD-1) therapy that works by helping increase the ability of the body's immune system to help detect and fight tumour cells. KEYTRUDA ® is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumour cells and healthy cells. KEYTRUDA ® was first approved in Canada in 2015 and currently has indications in several disease areas, including advanced renal cell carcinoma, bladder cancer, non-small cell lung carcinoma, primary mediastinal B-cell lymphoma, classical Hodgkin lymphoma, colorectal cancer, endometrial carcinoma, cervical cancer, esophageal cancer, triple-negative breast cancer, melanoma, and head and neck squamous cell carcinoma. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable, and healthy future for all people and communities. For more information about our operations in Canada, visit and connect with us on LinkedIn @MerckCanada. Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA This news release of Merck & Co., Inc., Rahway, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2023 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site ( ® Merck Sharp & Dohme LLC. Used under license. © 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. CA-NON-04264 Media Contacts:
Cision Canada
36 minutes ago
- Cision Canada
Praxis Spinal Cord Institute, Technology for Living and MIMIC Systems Vancouver pilot Novel Solid-State Cooling and Heating System Advancing Climate Resiliency for People with Disabilities
Pilot marks Canadian first in climate-resilient, refrigerant-free heating & cooling technology to assess climate equity. VANCOUVER, BC, Aug. 13, 2025 /CNW/ - Through the SCI Climate Futures initiative, Praxis Spinal Cord Institute and Technology for Living (TFL) are advancing innovative solutions to support the health resiliency of individuals vulnerable to rising temperatures. Today, Praxis and TFL are proud to announce the successful installation of the first pilot MIMIC solid-state climate control system in the Vancouver home of an individual living with spinal cord injury (SCI). This milestone was made possible with the generous support of the Gore Mutual Insurance Collaborative Climate and Equity Partnerships grant. For individuals living with SCI, multiple sclerosis (MS), and other chronic conditions that impair the body's natural ability to regulate temperature, prolonged exposure to heat, especially temperatures exceeding 29°C can be life-threatening. Without access to effective cooling technologies, these individuals face daily health risks, including muscle spasms, disorientation, and hospitalization. "At Gore Mutual, we believe that climate resilience must be inclusive. Supporting innovative solutions like the MIMIC system aligns with our commitment to equity and sustainability," said Gaby Polanco Sorto, VP, Purpose, Sustainability and Office of the CEO at Gore Mutual Insurance. "As the founding partner of The Climate and Equity Lab, we remain committed to deepening our collective understanding of how climate change impacts vulnerable communities, and we're proud to partner with organizations that are creating real-world impact for Canadians living with disabilities." MIMiC Systems unveils a solid-state solution for indoor climate control for the built environment, designed to eliminate refrigerants or moving parts. Offering both heating and cooling in a single, compact unit, the system provides a quiet alternative to traditional HVAC, ideal for property owners seeking simplicity, sustainability, and performance. The installation faced several delays due to the complexity of approving novel clean tech in BC, with support from the City of Vancouver essential to the launch of the pilot, highlighting the need for regulatory change to effectively meet the climate resiliency needs of Canadians living with disabilities. "It's been a great experience. The unit is beautiful, and we're really happy our family was chosen for the pilot. Just walking into a cool home makes such a difference. I hope this system helps us stay comfortable while using less energy during the summer"— Pilot PLEX (person with spinal cord injury, lived experience) homeowner. " We're building a new standard for thermal comfort - one that's easy to install, built to last, and aligned with our planet's needs.", said Berardo Matalucci, CEO of MIMiC. "SCI Climate Futures initiative helped us to deploy our first unit to provide heating and cooling to those who need it the most. We're humbled and grateful for all the support. We'd also like to give a huge shoutout to Terra Mechanical Ltd. They've been a fantastic partner for our first install". The installation was completed by Terra Mechanical Ltd., BC HVAC and controls specialists, with support from the MIMIC, Praxis, and TFL teams. It involved close collaboration with the homeowner and building management to ensure compatibility, accessibility, and safety. Valuable feedback gathered during the process is already informing future product refinements. Why It Matters The SCI Climate Futures initiative was launched in response to British Columbia's escalating heat crises, which disproportionately affect people with disabilities. Phase 2 expands the scope to test and validate built-environment technologies that offer year-round thermal regulation. "At Technology for Living, we believe equitable access to assistive technology is essential for the well-being and independence of people with disabilities. This pilot is a powerful example of how inclusive innovation can reduce health risks and support safer, more sustainable living environments." said Ean Price, Innovation Strategist, Technology for Living. "This pilot project is a critical step forward for our SCI Climate Futures initiative," said Bill Barrable, CEO of Praxis Spinal Cord Institute. "The project signifies our dedication to advancing innovative, climate-resilient solutions that protect the health and safety of people with spinal cord injuries and others who are vulnerable to extreme heat. At the core of our mission is improving the lives of individuals living with SCI, especially for those most vulnerable to rising temperatures." Next Steps MIMIC Systems will continue working with the pilot household to monitor performance, energy usage, and user experience, while providing ongoing technical support. A second pilot installation site has already been confirmed and is scheduled for deployment in the coming months. This milestone represents a key step toward a climate-resilient future, one that centers on inclusion, accessibility, and sustainability. About Praxis Spinal Cord Institute Praxis Spinal Cord Institute is a Vancouver-based not-for-profit organization that leads global collaboration in spinal cord injury research, innovation, and care. We accelerate the translation of discoveries and best practices into improved treatments for people with spinal cord injuries. Learn more: About Gore Mutual Built on a foundation of financial strength for more than 180 years, Gore Mutual Insurance Company is one of the oldest property and casualty mutual insurers in Canada. With offices in Cambridge, Toronto and Vancouver, Gore Mutual is a Canadian mutual company offering competitive insurance products through trusted broker partners. Every decision and investment made is anchored in the long-term benefits to customers, members and communities. For more information, please visit About Technology for Living Technology for Living (TFL) supports people with severe physical disabilities in living as independently as possible. TFL provides individuals who experience physical barriers with peer support, innovative technologies, respiratory therapy services, and equipment that address unmet needs and promote independence, inclusion, and well-being. Learn more: About MIMIC Systems MIMiC Systems is pioneering solid-state, refrigerant-free heat pump technology to reduce the climate impact of heating and cooling. Unlike traditional systems that depend on compressors and leak high-GWP refrigerants, MIMiC's solution is a quiet, reliable, and emission-free alternative. Our mission is to accelerate the transition to resilient and sustainable heating and cooling systems in buildings and beyond. Learn more:
Cision Canada
3 hours ago
- Cision Canada
ModuleMD Ranks No. 585 on the 2025 Inc. 5000 List of America's Fastest-Growing Private Companies
Innovative Healthcare Technology Company Recognized for Growth, Impact, and Excellence GRAND BLANC, Mich., Aug. 13, 2025 /CNW/ -- Inc., the leading media brand and playbook for the entrepreneurs and business leaders shaping our future, today announced that ModuleMD ranks No. 585 on the annual Inc. 5000 list, the most prestigious ranking of the fastest-growing private companies in America. The list provides a data-driven snapshot of the most successful companies within the economy's most dynamic segment—its independent, entrepreneurial businesses. Past honorees include companies such as Microsoft, Meta, Chobani, Under Armour, Timberland, Oracle, and Patagonia. "This recognition is not just about growth—it's about the grit and heart of the clinicians we serve," said Abhinay Rao, CEO of ModuleMD. "Every product we build stems from a real conversation with a healthcare hero. This ranking validates our mission to reduce burnout, simplify care delivery, and elevate the joy of practicing medicine." This year's Inc. 5000 honorees have demonstrated exceptional growth while navigating economic uncertainty, inflationary pressure, and a fluctuating labor market. Among the top 500 companies on the list, the median three-year revenue growth rate reached 1,552 percent, and those companies have collectively added more than 48,678 jobs to the U.S. economy over the past three years. "Making the Inc. 5000 is always a remarkable achievement, but earning a spot this year speaks volumes about a company's tenacity and clarity of vision," says Mike Hofman, editor-in-chief of Inc."These businesses have thrived amid rising costs, shifting global dynamics, and constant change. They didn't just weather the storm—they grew through it, and their stories are a powerful reminder that the entrepreneurial spirit is the engine of the U.S. economy." Methodology Companies on the 2025 Inc. 5000 are ranked according to percentage revenue growth from 2021 to 2024. To qualify, companies must have been founded and generating revenue by March 31, 2021. They must be U.S.-based, privately held, for-profit, and independent—not subsidiaries or divisions of other companies—as of December 31, 2024. (Since then, some on the list may have gone public or been acquired.) The minimum revenue required for 2021 is $100,000; the minimum for 2024 is $2 million. As always, Inc. reserves the right to decline applicants for subjective reasons. A Milestone Year of Recognition and Celebration 2025 has been a landmark year for ModuleMD —not only for achieving a spot on the Inc. 5000 list for the first time but also for celebrating 25 years of innovation in specialty healthcare. Earlier this year, ModuleMD proudly marked its silver anniversary at the AAAAI Annual Meeting, where the company unveiled the next generation of its AI-driven solutions and honored its long-standing partnerships with Allergy, Pulmonology, and ENT practices across the country. This momentum continues as ModuleMD prepares to showcase its full suite of offerings this November at ACAAI 2025, highlighting how its intelligent platforms are transforming workflows, enhancing reimbursement, and reducing provider fatigue. About ModuleMD ModuleMD is a healthcare technology company based in Grand Blanc, Michigan, delivering EHR-integrated solutions designed for Allergy, Pulmonology, and ENT practices. Built with clinician insight, ModuleMD combines AI, automation, and specialty-specific tools to streamline care and reduce administrative burden. Key Solutions: EHR & PM – Unified platform for documentation, scheduling, and compliance. RCM Services – End-to-end billing support to maximize reimbursement. Immunotherapy Module – Designed for allergy practices to manage formulations and inventory. Infusion Management – Tools for biologic tracking, scheduling, and compliance. JOSH – Multilingual AI dictation with real-time transcription and smart pause/resume. SPOCK – Front office automation with smart messaging and communication tools. InDrA ModuleMD has been recognized as a G2 High Performer (2022–2025) and a Top 100 Healthcare Technology Company (2023) for its innovation and impact in specialty care. To know more about ModuleMD, visit Media Contact: Cheryl Fernandes Director, Digital Marketing [email protected] Join the Community.
